Akcea Therapeutics, Inc. (NASDAQ:AKCA) is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, AKCA to report 2Q20 loss of $ 0.35 per share.
For the full year, analysts anticipate top line of $ 112.53 million, while looking forward to loss of $ 1.63 per share bottom line.
Previous Quarter Performance
Akcea Therapeutics, Inc. came out with loss for the first quarter of $ 0.42 per share, from the revenue of $ 16.07 million. The quarterly revenues fell 90.48 percent compared with the same quarter last year. According to street consensus, AKCA was expected to report 1Q20 loss of $ 0.46 per share from revenue of $ 34.85 million. The bottom line results beat street analysts by $ 0.04 or 8.70 percent, at the same time, top line results fell short of analysts by $ 18.78 million or 53.89 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Akcea Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of AKCA was $ 10.92, representing a 36.50 % increase from the 52 week low of $ 8.00 and a 54.46 % decrease over the 52 week high of $ 23.98.
The company has a market capital of $ 1.11 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AKCA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Akcea Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.akceatx.com
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
